Right to Life Act

A Bill to Establish Protections, Standards, and Research Support for Ectogenesis, Ensure the Intrinsic Rights of the Unborn, Address Declining Birthrates, and Provide Universal Access to Expectant Mothers

Preamble

- Whereas every human life possesses inherent dignity and inalienable rights from the moment of conception, marked by the zinc spark;

- Whereas drastically declining birthrates worldwide threaten societal stability, economic vitality, and the continuation of human civilization;

- Whereas ectogenesis offers a transformative means to preserve life, prevent disease, and reverse demographic decline while respecting maternal autonomy;

- Whereas advancing ectogenesis research and development (R&D) is a moral and strategic imperative to protect the unborn, ensure U.S. scientific leadership, and secure a sustainable future;

This Act establishes a unified framework for the ethical, secure, and accessible development and application of ectogenesis, prioritizing the God-given rights of the unborn, addressing global birthrate declines, and eliminating barriers to scientific progress.

Section 1: Definitions

Zinc Spark: The biochemical event at conception, observable as a burst of zinc fluorescence, marking the initiation of an embryo’s intrinsic rights.

Ectogenesis: The process of gestating a human fetus outside the maternal womb in an artificial environment designed to replicate optimal developmental conditions.

Advocate Guardian: A court-appointed representative, parent, adoptive parent, or foster caregiver with legal authority to act in the best interests of the unborn child during ectogenesis.

Proactive Genetic Correction: AI-driven genetic editing to prevent or correct disease markers or developmental abnormalities, excluding non-therapeutic modifications (e.g., aesthetic or performance-enhancing traits).

Section 2: Recognition of Intrinsic Rights

The intrinsic right to life of every human embryo is recognized from the moment of the zinc spark.

Embryos in ectogenesis shall be afforded the same legal protections as persons born, including the right to an optimal developmental environment and protection from harm.

Section 3: Addressing Declining Birthrates

National Priority: Ectogenesis is declared a national priority to address drastically declining birthrates, recognized as a threat to societal and economic stability.

Policy Goals: The development and deployment of ectogenesis shall aim to:

Increase access to life-affirming reproductive technologies for expectant mothers.

Support families and individuals facing infertility or pregnancy challenges.

Ensure the continuation of human populations through ethical means.

Reporting: The Department of Health and Human Services shall annually report to Congress on ectogenesis’s impact on birthrates, including adoption and foster care outcomes.

Section 4: Standards for Ectogenesis

Optimal Environment: Ectogenesis facilities shall provide an artificial womb environment that replicates the natural womb’s functions, including:

Nutrient and oxygen delivery via an artificial placenta.

Temperature, fluid, and sensory conditions conducive to healthy development.

Continuous monitoring by AI systems and licensed medical professionals to ensure proper nutrition and preventative intervention.

Genetic Correction Policy:

Proactive genetic correction is permitted to prevent or correct disease markers or developmental abnormalities identified by AI, subject to:

- Approval by the National Ectogenesis Oversight Board.

- Use of minimally invasive techniques to preserve embryonic viability.

- Non-therapeutic genetic modifications (e.g., for aesthetic or performance traits) are prohibited.

AI and Human Monitoring:

AI systems shall monitor fetal health metrics (e.g., heart rate, growth, nutrient uptake), detect disease markers, and alert medical staff to anomalies.

Human oversight by trained ectogenesis specialists shall validate AI recommendations and perform interventions.

Customization for Religious or Therapeutic Preferences:

Parents or advocate guardians may request AI-assisted customization, including:

- Playback of religious texts, prayers, or music.

- Therapeutic recordings (e.g., parental voices) to promote neurological development.

- Interactive visitation protocols (e.g., video/audio communication), where feasible.

Customizations must align with the child’s best interests and be approved by medical staff.

Section 5: Security and Access Protections

Restricted Access: Sole access to the unborn child during ectogenesis shall be granted to:

Biological parents, unless they relinquish rights.

Adoptive parents, foster caregivers, or court-appointed advocate guardians.

Licensed ectogenesis medical staff for necessary interventions.

Air-Gapped Security Measures:

Ectogenesis facilities shall implement air-gapped systems to isolate critical data and AI operations from external networks, preventing unauthorized access or cyberattacks.

Specific technical standards for air-gapped systems shall be developed by cybersecurity experts in consultation with the National Ectogenesis Oversight Board.

Facilities shall use biometric authentication (e.g., fingerprint, facial recognition) and maintain auditable access logs.

Privacy: The identity and medical records of the unborn child, parents, and guardians shall be protected under federal privacy laws, with disclosures limited to legal or medical necessity.

Section 6: Maternal Autonomy and Universal Access

Pro-Life and Pro-Choice Framework:

Expectant mothers retain the right to choose whether to continue a pregnancy.

Should a mother opt for termination, the embryo shall be transferred to an ectogenesis facility, where the state or an advocate guardian assumes responsibility for the child’s development.

Universal Access:

Ectogenesis services shall be available to all expectant mothers, regardless of financial status, race, religion, or decision to continue or terminate a pregnancy.

The federal government shall establish a funding mechanism to subsidize ectogenesis for low-income mothers, ensuring equitable access.

Informed Consent:

Mothers shall receive comprehensive counseling on ectogenesis, including risks, benefits, and rights to relinquish or retain parental responsibilities.

Consent for ectogenesis shall be voluntary and revocable only within a medically safe window, as determined by experts.

Section 7: Role of Advocate Guardians

In cases where biological parents relinquish rights, the state shall appoint an advocate guardian to represent the unborn child’s interests during ectogenesis.

Advocate guardians shall:

- Ensure compliance with the child’s religious or cultural preferences, where specified.

- Facilitate adoption or foster care arrangements post-gestation.

- Monitor developmental progress in collaboration with medical staff.

Section 8: Research and Development for Ectogenesis

Federal Funding Authorization:

The Department of Health and Human Services shall allocate funds for ectogenesis R&D, including grants for artificial womb technologies, artificial placenta development, and clinical trial preparation.

Research involving human embryos is permitted with donated embryos, subject to ethical review by the National Ectogenesis Oversight Board.

This provision supersedes conflicting restrictions in federal appropriations laws (e.g., Dickey-Wicker Amendment) for ectogenesis-specific research.

Elimination of 14-Day Rule:

The 14-day limit on in vitro human embryo research is repealed for ectogenesis R&D, allowing studies beyond 14 days to develop full-term gestation technologies.

All research must prioritize embryonic viability and comply with ethical guidelines set by the Oversight Board, ensuring respect for the embryo’s intrinsic rights.

Preemption of State Restrictions:

State laws prohibiting or unduly restricting ectogenesis R&D shall be preempted to ensure a uniform national framework, provided research complies with federal ethical standards.

FDA Accelerated Pathway:

The Food and Drug Administration shall establish an accelerated approval pathway for ectogenesis devices and systems, prioritizing safety, efficacy, and ethical considerations.

The FDA shall collaborate with the Oversight Board to streamline clinical trial protocols for human ectogenesis.

Domestic R&D Priority:

To ensure U.S. scientific leadership and independence, the Department of Health and Human Services shall prioritize domestic R&D, minimizing reliance on international advancements.

International collaboration is permitted only when it aligns with U.S. ethical standards and national interests, as determined by the Oversight Board.

Public-Private Partnerships:

The Department shall incentivize private-sector investment in ectogenesis R&D through tax credits, matching grants, and intellectual property protections.

Section 9: Ethical and Regulatory Oversight

National Ectogenesis Oversight Board:

A federal board shall be established, comprising bioethicists, medical experts, religious leaders, and legal scholars, to regulate ectogenesis R&D and facilities.

The board shall set standards for licensing, staff training, AI certification, genetic correction protocols, and embryonic research beyond 14 days.

Ethical Guidelines:

Ectogenesis R&D and application shall prioritize the sanctity of life, the child’s best interests, and the reversal of declining birthrates.

Research on viable embryos without ethical approval is prohibited.

Inspections and Accountability:

Facilities and R&D programs shall undergo annual inspections to ensure compliance.

Violations (e.g., unauthorized genetic editing, security breaches) shall result in penalties, including fines, license revocation, or criminal prosecution.

Section 10: Public Engagement and Education

The Department of Health and Human Services shall fund public education campaigns to:

- Promote ectogenesis as a life-affirming solution to declining birthrates and infertility.

- Address ethical concerns about R&D, genetic correction, and extended embryonic research.

- Build bipartisan support for the Act’s pro-life/pro-choice framework.

Campaigns shall leverage platforms like X to counter misinformation and highlight the Act’s commitment to protecting life and ensuring demographic stability.

Section 11: Funding and Implementation

The Department of Health and Human Services shall allocate funds for:

- Ectogenesis R&D, facility construction, and operation.

- Training for medical, AI, and cybersecurity staff.

- Public education and access subsidies.

Implementation shall begin within 24 months of enactment, with pilot programs in regions with high infertility rates or declining birthrates.

Section 12: Severability

If any provision is found unconstitutional or unenforceable, the remaining provisions shall remain in effect.

Section 13: Effective Date

This Act shall take effect 180 days after passage.